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Management of Hyperglycemia in Acute Stroke
How, When, and for Whom?
Michael T. McCormick, MRCP; Keith W. Muir, MD, FRCP;
Christopher S. Gray, MD, FRCP; Matthew R. Walters, MD, FRCP
Current acute therapies for ischemic stroke are limited.Only a small proportion of stroke patients are eligible to
receive fibrinolytic therapy; clinical trials of neuroprotectant
drugs have yielded disappointing results, and other potential
interventions are at very early stages of development.
Against this background, coordinated stroke unit care is,
however, of proven benefit; reduced mortality, institutional-
ization and dependency. Clinical trials demonstrating the
benefit of stroke unit care have recognized the potential but
unproven benefits that may be realized through rigorous
physiological monitoring and intervention to correct derange-
ments in the acute phase.
This review will discuss the complex relationship between
hyperglycemia and stroke, with particular emphasis on the
role of glycemic control in the acute stroke patient.
Whether acute hyperglycemia is a cause of neurological
deterioration or an epiphenomenon, is a distinction pivotal in
management of the stroke patient with hyperglycemia. Post-
stroke hyperglycemia is common and, at least in nondiabetic
individuals, is associated with a poorer stroke outcome when
compared to normoglycemia.1,2 In a systematic review of
observational studies examining the prognostic significance
of hyperglycemia in acute stroke, the unadjusted relative risk
of in-hospital or 30-day mortality was 3.07 (95% CI, 2.50 to
3.79) in nondiabetic patients and 1.30 (95% CI, 0.49 to 3.43)
in those with diabetes.3 The relative risk of poor functional
outcome in hyperglycemic nondiabetic patients was 1.41
(95% CI 1.16 to 1.73). Using MRI it has been demonstrated
that in patients with acute perfusion diffusion mismatch
within 24 hours of stroke onset, acute hyperglycemia corre-
lates with reduced salvage of mismatch tissue from infarction,
greater final infarct size, and worse functional outcome.4 As
a consequence, not only has a causal relationship between
hyperglycemia and poor outcome been assumed, but also a
benefical treatment effect from control of hyperglycemia (as
reflected in local, national and international management
guidelines). Prospective trial data for such a treatment effect
have been lacking and in the absence of randomized trial
evidence, clinical practice has been guided by extrapolation
of results from nonstroke populations that inform consensus
guidelines.5 The absence of optimal quality evidence in this
area has been recognized, and evidence derived from patients
with acute stroke is becoming available. Recent data will be
reviewed and discussed.
Diabetes or Poststroke Hyperglycemia?
Stroke is predominantly a disorder of older people in whom
the prevalence of previously recognized type 2 diabetes is
approximately 7%. Depending on the diagnostic criteria used,
a further 7.7 to 14.8% of persons over 65 years of age may
have previously unrecognised type 2 diabetes.6
In any given stroke population the prevalence of diabetes is
approximately 8% to 20%, with a further 6% to 42% having
evidence of previously unrecognized diabetes before the
acute event.2,7–11 Such estimates are, however, complicated
by the high prevalence of poststroke hyperglycemia; in one
series of acute stroke patients it was estimated that up to 68%
had poststroke hyperglycemia, defined by a plasma glucose
concentration 6.0 mmol/L.2
It is possible that poststroke hyperglycemia is primarily a
stress response in relation to stroke size and severity12:
however, poststroke hyperglycemia is prevalent across all
clinical subtypes and severities of stroke and is not restricted
to those most severely affected.10,13 Although some studies
have suggested that stress hyperglycemia may occur as a
result of neuroendocrine dysregulation in response to insular
cortex lesions,14 this finding has not been replicated by
others.15 It remains unclear whether hyperglycemia arises as
an epiphenomenon of stroke in general, as a consequence of
specific anatomic involvement, or as a reflection of underly-
ing dysglycemia.
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Insulin and Stroke Units: Current Practice
American and European guidelines advise active treatment of
hyperglycemia. The criteria for implementation of insulin
treatment vary, with European Stroke Initiative (EUSI) guide-
lines advising intervention if blood glucose exceeds
10 mmol/L, whereas the American Stroke Association (ASA)
now advocates a threshold of 11 mmol/L.5 In an audit of acute
neurological stroke care performed across 22 countries by the
European Federation of Neurological Societies, the mean
threshold of blood glucose concentration for intervention was
10.6 mmol/L, ranging from 7.4 to 14.0 mmol/L in different
countries.6 The survey did not reveal the variation in practice
among centers within individual countries, which we presume
to be at least as great. The blood glucose level used to define
poststroke hyperglycemia (PSH), and thus the level at which
a worse stroke outcome is anticipated, also varies. Poststroke
hyperglycemia has been defined using thresholds between 6.1
and 8.0 mmol/L, based on random or fasting blood glu-
cose,10,16,17 with some studies including patients presenting
up to 72 hours from ictus.16 Factors influencing PSH may
include a variable combination of neuroanatomical, neuroen-
docrine, and general metabolic features. In addition, extrane-
ous factors such as time from ictus to sampling, early feeding,
and intravenous support will influence plasma glucose levels.
A recent study examining the effect of blood glucose on
infarct size as measured using MRI found that persistent
hyperglycemia (defined as blood glucose 7.0 mmol/L) in
the 72 hours after acute stroke was associated with an
increase in infarct size and worse stroke outcome.18 The
decision to intervene is made more complex by the risk of
iatrogenic hypoglycemia during insulin treatment. This needs
to be considered when selecting the most appropriate glucose
level, the method and duration of insulin delivery, and the
duration of glycemic monitoring.
A variety of methods of insulin administration exist,
comprising continuous intravenous (IV) infusion, repeated
subcutaneous dosing by sliding scale, or IV delivery of a
reconstituted infusion containing insulin and dextrose with
potassium supplementation (the GKI regime). Sliding scale
regimens are largely reactive, correcting changes as and when
they occur, whereas GKI regimens are largely proactive,
predicting insulin requirements and maintaining euglycemia
within a therapeutic range. Concurrent administration of
insulin, potassium and glucose as a GKI infusion may
theoretically reduce the risk of hypoglycemia arising as a
result of device or infusion failure.
Maintenance of euglycemia can prove difficult in patients
who are eating and drinking normally, as such patients tend to
develop postprandial hyperglycemia before the insulin infu-
sion rate is increased. Although both sliding scale and GKI
regimes have attracted criticism in the literature,19 no clearly
superior alternative has yet been reported.20 The practical
aspects and the safety profile of each method have been
considered in different hospital settings including critical
care, coronary care, general medical wards, and stroke units.
In the absence of trial data sufficiently powered to examine
the effect of insulin on clinical outcomes in a stroke popula-
tion, trials of insulin infusions in other contexts (such as
coronary and intensive care units) may yield some insights
into the potential effectiveness of methods of glucose lower-
ing in stroke.
Insulin Use Outwith Stroke Units
A meta-analysis of 35 randomized controlled trials involving
8478 patients examined the effect of insulin on mortality in
the hyperglycemic critically ill patient. Insulin was adminis-
tered as a GKI Infusion in 86% of the studies, with 14% using
intravenous insulin by pump. Studies were published between
1965 and 2002 and included patients primarily with acute
myocardial infarction (MI). Combined data demonstrated that
insulin decreased short-term mortality by 15% (RR 0.85; 95%
CI, 0.75 to 0.97). Greatest benefit was noted in the surgical
intensive care unit (ICU) population (RR, 0.58; 95% CI, 0.22
to 0.62), when the aim of therapy was glucose control (RR,
0.71; 95% CI, 0.54 to 0.93) and in patients with diabetes
mellitus (RR, 0.73; 95% CI, 0.58 to 0.90).21 Two multicenter
randomized controlled trials of GKI infusions in the context
of acute MI have clouded the picture. The Diabetes-Mellitus
Insulin-Glucose Infusion in Acute Myocardial Infarction 2
(DIGAMI 2) trial failed to reproduce the initial promising
results of the first DIGAMI trial.22 In contrast to the findings
in DIGAMI, in DIGAMI 2 GKI with or without long-term
insulin failed to demonstrate survival benefit over routine
treatment, likely because of the failure to attain sustained
glycemic control and a significant difference between treat-
ment and placebo groups.22
Additional results from the merger of 2 multicenter trials
(The Clinical Trial of Reviparin and Metabolic Modulation in
Acute Myocardial Infarction Treatment Evaluation, and Es-
tudios Cardiologicas Latin American Study Group:
CREATE-ECLA) which randomized 20 201 patients within
12 hours of acute ST-elevation MI to GKI-infusion or
placebo, found that GKI infusion had a neutral effect on
mortality, cardiac arrest, and cardiogenic shock.23
The more recent publication of the large single center
Leuven study that reported reduced mortality in a surgical
intensive care unit population treated with insulin to achieve
tight blood glucose control (4.4 to 6.1 mmol/L) has resulted
in its adoption in many intensive care facilities.24 Severe
nosocomial infections, acute organ dysfunction, and critical
illness neuropathy were prevented in patients treated with
intensive insulin. When the same group examined the effect
of insulin in 1200 patients admitted to a medical intensive
care unit with similar targeted levels of glucose control,
overall intensive care mortality was similar for both groups,
with a suggestion of benefit of tight control emerging only in
those patients who stayed in the intensive care unit for three
or more days.25,26 Both trial results have recently been pooled
to examine the controversies surrounding infusion duration,
optimal blood glucose thresholds, and effect on specific
subgroups. Intensive insulin therapy (IIT) reduced mortality
for both the intention to treat population and for patients
staying for 3 days, with no difference in patients resident
for 3 days. Mortality was more significantly reduced in
patients with a blood glucose 6.1 mmol/L when compared
to patients with a blood glucose 6.1 to 8.3 mmol/L or
8.3 mmol/L, despite a greater risk of hypoglycemia.26 Two
recent European multicenter trials (Glucontrol27 and NICE-
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Sugar28) have aimed to maintain tight glycemic control (4.4 to
6.1 mmol/L) in acutely ill patients. The Glucontrol trial was
stopped early after recruitment of 1100 patients, because of a
high rate of hypoglycemia in the intensive control group, and
an association of hypoglycemia with increased mortality. In
488 patients recruited to the Efficacy of Volume Substitution
and Insulin Therapy in Severe Sepsis (VISEP) trial,29 exam-
ining the effect of insulin in patients with severe sepsis and
septic shock, patients receiving insulin had a 6-fold increased
risk of significant hypoglycemia.
Although current evidence suggests that intensive glucose
lowering may be necessary to achieve a treatment effect,
recent evidence from the UK Glucose Insulin Stroke Trial
(GIST-UK)30 suggests that most acute stroke patients will
only have mild to moderate increases in plasma glucose at
presentation (median 7.6 mmol/L [IQR 6.7 to 9.0]) with
minimal insulin requirement as a consequence. Therefore, in
the management of acute stroke, intensive insulin regimens
are likely to require significant carbohydrate loading and
immediate supplemental feeding to reduce the risk of
hypoglycemia.
Insulin Use in Brain-Injured Patients
Limited evidence exists on the action of insulin in humans
with CNS injury. Post hoc analysis of 63 patients with
isolated brain injury from the larger Leuven cohort of 1548
surgical ICU patients examined the effect of insulin therapy
on intracranial pressure, diabetes insipidus, seizures, and
long-term rehabilitation at 6 and 12 months follow-up. Both
neurological and nonneurological morbidity was reduced in
the insulin group.31 In a retrospective study of 960 patients
with thromboembolic stroke, patients who had initial hyper-
glycemia that settled on repeated testing at 24 and 48 hours
had similar mortality rates to patients with persistent eugly-
cemia.32 Insulin, oral hypoglycemic agents, or both were used
in 63.7% of patients with hyperglycemia after admission.
These results suggested some association between blood
glucose control and outcome, providing justification for
prospective work in this area.
Recent Evidence in Stroke Patients
The GIST-UK study recruited patients with acute stroke and
blood glucose between 6.1 and 17 mmol/L regardless of
whether or not they were known to have diabetes, although
insulin requiring patients with diabetes were excluded.30
Patients were randomized to either control (normal saline) or
a GKI infusion for 24 hours. The objective of the GKI
treatment was to maintain capillary blood glucose between 4
and 7 mmol/L. The primary end point of the trial was
mortality at day 90. The GKI regime in GIST-UK comprised
500 mls of 10% dextrose, 20 mmol KCL, and 16 U (initial)
of soluble recombinant human insulin. At infusion initiation
blood glucose monitoring was undertaken hourly until eug-
lycemia was reached and then changed to 2-hourly. Insulin
dosage escalations or reductions required bag disposal and
adjustment attributable to the inflexibility of insulin titration
independent of glucose, and the median number of bag
changes over the 24 hours was 2 per patient. The GKI regime
is therefore labor-intensive.
A total of 933 patients were recruited. Median time to
infusion was less than 14 hours for both groups. Of the 464
acute stroke patients who were treated with the GKI infusion,
30% died within 90 days compared with 27.3% among the
469 patients who were randomized to receive saline solution
(P0.37). Similarly, no significant effect of GKI infusion on
prevalence of severe disability at 90 days was identified. One
unexpected finding was an effect of GKI infusion on blood
pressure. Treatment with GKI was associated with significant
decreases in blood pressure beyond that of medical therapy,
with a mean fall in systolic blood pressure of 9.03 mm Hg.
Although insulin is known to exert a vasodilatory effect on
resistance vessels,33 alternative explanations for this novel
observation include the effect of potassium as part of the trial
infusion or a pressor effect of alternate fluid therapy in the
control arm. Despite the neutral result the trial remains the
first large clinical trial of glucose modulation in acute stroke,
and subsequent trials will be informed through its results. The
triallists intended to recruit a proposed sample size of 2355
patients and as such the study was underpowered to detect the
prespecified mortality difference between groups. As previ-
ously discussed, despite a glucose enrolment range of 6.0 to
17 mmol/L, the majority recruited had mild hyperglycemia;
median blood glucose 7.8 mmol/L (6.8 to 9.2) in the GKI
group and 7.6 mmol/L (6.7 to 8.8) in the placebo group. The
effect of GKI on patients with moderate to severe hypergly-
cemia remains uncertain with current practice still being
guided by consensus guidelines. In contrast to the previously
published meta-analyses on insulin, which demonstrated
benefit in patients when the goal of therapy was glucose
lowering, GKI lowered glucose but the effect was only small
(difference between GKI and saline group’s 0.57 mmol/L)
and glucose concentration fell spontaneously with IV saline
alone. It is interesting to compare the neutral result of
GIST-UK with the neutral result of DIGAMI II, which saw a
0.9-mmol/L difference in blood glucose between the insulin
and placebo groups,22 whereby the positive DIGAMI study
achieved a 2.1-mmol/L reduction in glucose.21 A posthoc
analysis of GIST-UK investigating the safety of glucose
lowering on outcome found that patients receiving GKI with
a 2-mmol/L or more decrease in blood glucose between
baseline and 24 hours had a higher mortality at 24 hours (34%
53⁄154) when compared to patients with a glucose reduction of
less than 2 mmol/L over the same period (22% 41⁄188;
P0.009). The time window for targeted acute stroke therapy
remains uncertain, although more recent neuroprotective and
thrombolytic trials have adopted times limit of up to 6 hours
from ictus to maximize opportunity to attenuate tissue inju-
ry.34,35 In the GIST-UK study only 8 patients were treated
within 3 hours, with 108 patients being treated within 6 hours.
No patients in GIST-UK received thrombolysis and as such
any potential synergistic effect with GKI could not be
assessed.
The timing of insulin treatment after stroke may not
necessarily follow conventional windows for acute therapies,
as the timeframes for hyperglycemia to evolve may be
unrelated and dependent on other physiological and iatro-
genic factors.
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An alternative method of insulin administration using
intravenous insulin at a variable rate adjusted for target
glucose concentration of 5 to 8 mmol/L and run simulta-
neously with a crystalloid infusion of either normal saline or
5% dextrose was examined in a small randomized controlled
pilot study. Patients within 24 hours of an acute ischemic
stroke with hyperglycemia (8 to 20 mmol/L) were random-
ized to receive rigorous glycemic control or standard man-
agement for 48 hours. Twenty-five patients were recruited, 13
of whom were randomized to insulin infusion.36 In a further
study of IV insulin administration 24 patients within 12 hours
of an acute ischemic stroke with blood glucose 9.4 to
22.2 mmol/L received insulin for a mean of 54 hours (range
17 to 72 hours). At least 1 episode of hypoglycemia
occurred in 11 (46%) patients, with symptomatic hypogly-
cemia in 5 (21%).37
Two further trials are examining the insulin administration
in hyperglycemic acute ischemic stroke: the Glucose Regu-
lation in Acute Stroke Patients Trial (GRASP),38 which is
continuing recruitment, and the Treatment of Hyperglycemia
in Ischemic Stroke trial (THIS),39 which has completed
recruitment but not yet presented its results. In GRASP,
patients with hyperglycemia (glucose 6.1 mmol/L) within
24 hours of symptom onset are randomized to tight glucose
control (3.9 to 6.1 mmol/L), loose glucose control (6.1 to
11.1 mmol/L), or usual care. The insulin is delivered as a GKI
infusion and titrated to capillary glucose. The primary out-
come of the GRASP trial is rate of hypoglycemic events
(glucose 3.05 mmol/L) and definitive information on clin-
ical endpoints is not expected.
The THIS trial39 is a randomized, multi-center trial which
recruited patients with acute ischemic stroke within 12 hours
of symptom onset to usual treatment (subcutaneous insulin
four times daily) or aggressive treatment (continuous intra-
venous insulin to a target glucose range 6.1 to 7.2 mmol/L).
The experimental interventions continued for 72 hours. The
study recruited 45 patients, and as such it seems unlikely that
any statistically significant effect on clinical end points will
be discernible between groups.
Mechanisms of Injury and Potential Role
for Insulin
Evidence derived from animal models shows that during
acute focal and global ischemia, insulin therapy reduces
ischemic brain damage and may be neuroprotective.40 It is
postulated that the neuroprotective action is exerted through
insulin like growth factor (IGF) type receptors. Insulin and
IGF-1 were found to reduce ischemic damage when injected
directly into the brain ventricles.41 In a model of forebrain
ischemia in rats, insulin not only reduced histological injury
but improved neurobehavioural outcome.42 Insulin is also felt
to exert an anticoagulant effect, through reduced
thromboxane production43 and decreased plasminogen acti-
vator inhibitor-1 activity.44 The effect of insulin appears
dependent on the model of ischemia and also the method of
insulin administration. Studies examining the effect of insulin
on infarct size in animal models of focal ischemia demon-
strate differing results depending on the timing of insulin
relative to ischemia, duration of ischemia, and blood glucose
level obtained. In a transient focal model of cerebral ischemia
in rats, elevated blood glucose at the time of ischemia resulted
in larger infarcts than those with a blunted glucose effect.45
Development of hypoglycemia (mean blood glucose in the
range 3.2 to 3.8 mmol/L) in a cat model using insulin resulted
in larger infarcts and an increased death rate.46 Table 1
summarizes the effect of insulin on infarct volumes in
experimental models of focal ischemia.
There is evidence to support a beneficial effect of insulin
administration to achieve euglycemia in both preclinical
models of ischemia and in selected clinical scenarios.40,47
Animal studies indicate that this benefit is lost if hypoglyce-
mia occurs.48 Uncertainty remains as to whether insulin has
an effect independent of its action to lower glucose and
evidence exists of alternative mechanisms. In a rat model of
transient forebrain ischemia insulin administered with glu-
cose significantly reduced cortical and striatal neuronal ne-
crosis in the presence of normoglycemia, suggestive of a
neuroprotective effect of insulin independent of its hypogly-
cemic action.49 Various methods of neuroprotection have
been proposed, including a direct interaction with CNS tissue
via a growth factor effect. Use of a continuous intraventric-
ular infusion of low- and high-dose insulin or insulin like
growth factor 1 (IGF-1) in a transient forebrain model of
ischemia reduced neuropathological injury at 1 week com-
pared to placebo.41 Other possible actions have been sug-
gested: reduction of plasma free fatty acid (FFA) concentra-
tion occurs after GKI infusion in patients with MI.50 This may
be significant, as elevated FFA levels cause endothelial
dysfunction.51 It has previously been demonstrated in vitro
that insulin has an antiinflammatory effect on endothelial
cells.52 Some supportive evidence from human studies exists:
insulin infusion in patients with myocardial infarction re-
duced both C reactive protein and serum amyloid A protein at
24 and 48 hours compared to placebo.53 One further mecha-
nism underlying the antiinflammatory role of insulin relates
to the release of NO. Insulin increases expression of nitric
oxide (NO) synthase, the enzyme that generates NO. NO
downregulates the expression of endothelial cell adhesion
molecules as well as proinflammatory cytokines, resulting in
vasodilatation and improved blood flow.54 Insulin also has
anabolic properties, with stimulation of skeletal muscle pro-
tein synthesis promoting tissue repair and potentially affect-
ing rehabilitation.55
The “glucose paradox of cerebral ischemia” questions why
glucose, the main energy substrate for the brain, causes
demise of brain tissue at the time of cerebral ischemia.
Metabolism within penumbral tissue changes from aerobic to
anaerobic glycolysis. Anaerobic metabolism is less energy
efficient and produces lactate and unbuffered hydrogen ions.
Experimental models have consistently shown that animals
made hyperglycemic before induction of ischemia have
higher levels of lactate than euglycemic controls.56,57 Hyper-
glycemia may initially be neuroprotective, with increased
glucose available for metabolism and ATP production. Per-
sisting anaerobic metabolism results in the development of
intracellular acidosis. It has been shown using both pH-
sensitive microelectrodes and 31P nuclear magnetic resonance
spectroscopy that the brain pH of animals pretreated with
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glucose is considerably more acidotic than saline treated
controls.58,59 Acidosis may exacerbate penumbral injury
through enhancement of free radical formation, activation of
pH dependent endonucleases, and glutamate release with
subsequent alteration of intracellular Ca2 regulation and
mitochondrial failure.60–63
There is currently no direct proof that lactate is detrimental
to the ischemic brain. In vitro work using murine hippocam-
pal slices has shown that glucose and acidosis are detrimental
to cells whereas lactate is not.64 Using PET scanning it has
been shown that lactate may be the preferred energy supply to
the brain especially during times of stress.65 This is relevant
to the management of hyperglycemia in acute ischemic stroke
patients. If the ischemic brain is dependent on lactate for its
source of energy, targeted euglycemia may result in less
glucose load to the brain and thus less substrate for anaerobic
metabolism, therefore attenuated lactate production. Periin-
farct depolarisations (PIDS) which contribute to infarct ex-
pansion in focal ischemia models were found to be more
frequent66 in a cat model of middle cerebral artery occlusion
and associated with lower plasma glucose and a worse
outcome.67 The same group have demonstrated in a single
patient with traumatic brain injury complete disappearance of
cortical glucose dialysate coinciding with a period of hypo-
glycemia associated with an insulin infusion.68 This is con-
sistent with the effect of hypoglycemia on infarct progression
in animal models and emphasizes importance of strict mon-
itoring in patients receiving insulin. The lower limit for
glucose control in recent randomized trials is 3.9 to 4.0 mmol/
L.30,37 It is possible that this figure may need to be revised
upwards in future trials.
Patient Selection
Identification of appropriate patients that may benefit from
glucose lowering therapy requires knowledge of the temporal
profile of blood glucose post ictus. In patients with first blood
glucose measurement an average of 2.5 hours after onset,
glucose concentration increased in the first 12 hours after
stroke in 68% of subjects, the increase correlating with
greater stroke severity.69 In the first 231 patients randomized
to the placebo arm of the GIST-UK, mean blood glucose was
lower at 8 hours after commencement of placebo infusion.30
Using a continuous subcutaneous monitor measuring intersti-
tial glucose over a 72-hour period, blood glucose decreased
from a peak at 8 hours after stroke, reached its lowest level at
14 to 16 hours, reached a plateau, and then exhibited a further
late hyperglycemic phase at 48 to 88 hours after stroke.70
Elevated admission blood glucose after stroke may reveal
latent dysglycemia. In a study of 62 patients screened at 3
months after an acute ischemic stroke when admission blood
glucose was 6.1 mmol/L, 21% had diabetes mellitus and
37% had impaired glucose tolerance. A blood glucose
6.1 mmol/L and HbA1c 6.2% on admission had an 80%
positive predictive value for diabetes at 12 weeks.71 Patients
Table 1. Effect of Insulin on Infarct Volumes in Experimental Models of Focal Ischemia Using Permanent or Temporary Occlusion
Reference Species Site of Ischemia Occlusion Type Results
Yip et al45 Rat MCAO Temporary Intraischemic normoglycemia resulted in significantly smaller
infarct volumes than hypoglycemic rats
Zhu et al48 Rat MCAO Temporary Insulin was not beneficial in reducing infarction size. The increased
damage induced by insulin occurred in animals with very low
blood sugars (2 to 3 mmol/l)
Hamilton et al83 Rat MCAO Temporary Reduction in blood glucose to the low normal range (3 to
4 mmol/l) reduced infarction size, whereas insulin administration
without hypoglycemia did not
Fukuoka et al84 Gerbil UCCO Temporary Daily insulin injections without hypoglycemia resulted in least
infarction on histology
Zhao et al85 Rat MCAO Temporary Oedema formation was less in rats treated with insulin that
resulted in normal blood glucose levels
de Courten-Myers
et al46
Cat MCAO Temporary Insulin induced hypoglycemia resulted in increased infarct size in
cat survivors
Permanent Hyperglycemic cats receiving insulin had larger infarct sizes than
cats receiving normal saline
Nedergaard et al86 Rat MCAO Permanent Volume of infarction was decreased in hypoglycemic animals
Bomont et al87 Rat MCAO Permanent Insulin treatment in diabetic rats significantly reduced infarct
volume (by approximately 30%)
Izumi et al88 Rat MCAO Permanent Insulin and magnesium chloride in combination maximally reduced
infarct volume size
Izumi et al89 Rat MCAO Permanent Insulin given after MCA occlusion reduced infarction volume
without inducing sustained hypoglycemia
Kazan et al90 Rat MCAO Permanent Infarct volume was significantly reduced for rats receiving insulin
when compared to controls
Combs et al91 Cat MCAO Permanent No significant difference in infarct size between hyperglycemic rats
and rats with hyperglycemia receiving insulin
MCAO indicates middle cerebral artery occlusion; UCCO, unilateral common carotid artery occlusion.
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with “stress” hyperglycemia have an unadjusted relative risk
of in-hospital or 30-day mortality associated with admission
glucose levels 6.0 to 8.0 mmol/L of 3.07 (95% CI, 2.50 to
3.79) whereas in patients with diabetes it is 1.30 (95% CI,
0.49 to 3.43).72 The prevalence of established diabetes in
studies examining the role of hyperglycemia on stroke out-
come ranges from 7.4% to 33%.73,74 Identification of diabetes
at presentation usually results in additional monitoring of
blood glucose and a lower threshold for intervention to treat
hyperglycemia: it may be that the apparent difference in
outcome between known diabetic and simply hyperglycemic
stroke patients is related to the lower threshold for
intervention.
Hyperglycemia and Fibrinolytic Therapy
Restoration of cerebral blood flow with salvage of penumbral
tissue is the aim of thrombolysis.75 In a posthoc analysis of
the NINDS study hyperglycemic patients had a significantly
increased odds of symptomatic intracerebral hemorrhage and
reduced odds of a good clinical outcome.76
It is biologically plausible that recanalization may augment
the injurious effect of hyperglycemia. Using transcranial
Doppler ultrasound (TCD) to assess recanalization after
thrombolysis in 73 patients, hyperglycemia was an indepen-
dent predictor of poor outcome at 3 months in patients who
recanalized but not in patients with permanent occlusion.77
This finding may reflect the observation that early recanali-
zation is associated with a larger penumbral area susceptible
to the adverse effects of hyperglycemia.78 Using MR to
measure infarct progression in patients receiving intravenous
thrombolysis, infarct growth was more apparent in hypergly-
cemic patients compared to normoglycemic patients.79
Acute hyperglycemia has recently been shown to predict
nonrecanalization in the hyperacute phase of stroke80 and is
associated with poor outcome. Acute hyperglycemia may
exert an antifibrinolytic effect through glycation of annexin
II,81 and there is some suggestion that hyperglycemic patients
may derive more benefit form adjunctive measures to en-
hance the lytic effect of rt-PA.82 On the basis of these findings
it is plausible that maintenance of euglycemia at initial
presentation and continued through to recanalization may
enhance the effect of thrombolysis. Tables 2 and 3 summarize
studies of the relationship between admission glucose level
and outcomes in clinical trials of anticoagulant and
thrombolytic agents and the effect of blood glucose on lesion
volume progression measured using MRI surrogate markers
in clinical studies of patients with acute ischemic stroke.
Conclusions and Recommendations
Although experimental evidence supports a causal relation-
ship between hyperglycemia and adverse outcome after
stroke, trial data do not yet support intervention with insulin.
Current guidelines advise lowering of blood glucose but
disagree on the threshold at which to intervene, and make no
comment on specific insulin treatment regimes or treatment
targets. The heterogeneity of the stroke population may mean
that standard protocols should and cannot be applied to all
patients. Nutritional intake varies between stroke patients,
and adjustment for oral intake is difficult in the following
stroke maintenance of the targeted glucose level. The impor-
Table 2. Relationship Between Admission Glucose Level and Outcomes in Clinical Trials of Anticoagulant and Thrombolytic Agents
Reference
Time
Window Therapeutic Agent
No. of
Patients Study Parameters Results
TOAST92 24 hours Low molecular weight
heparinoid vs placebo
1259 Relationship between
admission blood glucose and
clinical outcome
All strokes combined: (OR0.82 for every 100 mg/dl
increase in blood glucose; P0.03)
Non lacunar strokes (OR 0.74 for every 100 mg/dl
increase in blood glucose; P0.02)
NINDS rt-PA
stroke trial76
3 hours Intravenous rt-Pa vs
placebo
624 NIHSS change of 4 at
3 months or a final score of 0
OR of neurological improvement per 100 mg/dl
increase in blood glucose0.76
(0.61 to 0.95) (P0.01)
Symptomatic ICH at 36 hours* OR of SICH per 100 mg/dl increase in blood
glucose1.75 (1.11 to 2.78) (P0.02)
PROACT II93 6 hours Intraarterial r-proUKIV
heparin vs IV heparin
alone
180 Symptomatic ICH within
36 hours of treatment**
Patients receiving r-proUK with admission blood
glucose 200 mg/dl experienced a 36% risk of
SICH compared to 9% for those 200 mg/dl
(RR 4.2; 95% CI 1.04 to 11.7) (P0.022)
CLOTBUST94 3 hours Intravenous thrombolysis
with randomisation to
TCD or placebo
117 Interaction between admission
glucose and ultrasound with
respect to good clinical
outcome (mRs 0 to 2)
High admission glucose predicted a lower probability
of good outcome in the control group but not the
active ultrasound group, as demonstrated by an
interaction between glucose and treatment
group (P0.043)
TOAST indicates Trial of ORG 10172 in Acute Stroke Treatment; NINDS, National Institute of Neurological Disorders and Stroke; PROACT II, PROlyse for Acute
Cerebral Thromboembolism; CLOTBUST, Combined Lysis Of Thrombus in Brain ischemia using transcranial Ultrasound and Systemic tPA; r-proUK, recombinant
pro-urokinase.
*SICH defined as CT documented hemorrhage within 36 hours of treatment that was temporally related to clinical deterioration.
**Presence of ICH with neurological deterioration defined as an increase of 4 points on the NIHSS in comparison with the preangiography score within 36 hours
of treatment initiation.
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tance and implications of early mobilization after stroke
discourages the use of prolonged infusions, contrasting sig-
nificantly with the immobile ventilated patient in intensive
care receiving enteral or parenteral nutrition and the acute MI
patient with staged mobilization. Extrapolation of animal data
and case series suggest that hypoglycemia may increase final
infarct size. Prevention of hypoglycemia is therefore impor-
tant and requires strict monitoring, but the threshold at which
hypoglycemia affects infarct progression is undetermined.
Application of intensive monitoring is dependent on appro-
priate staffing of stroke units and adherence to set protocols.
Different methods of insulin administration currently exist
and are being tested in randomized clinical trials. The
GIST-UK trial demonstrated that intervention with insulin in
the form of GKI infusion cannot be recommended routinely.
Many questions surrounding the role of glucose lowering
therapy remain unanswered; is intravenous infusion of insulin
at variable rate as opposed to the GKI infusion potentially
beneficial to patients with hyperglycemia? What level of
blood glucose is best for intervention? What is the therapeutic
time window? Will identification of the penumbra with CT
and MR imaging select appropriate patients? Is the effect of
insulin infusion affected by early recanalization of occluded
vessels? What effect would insulin have on outcome if it
impedes early mobilization? How long should the insulin
infusion last, with current knowledge of the variation in the
natural history of blood glucose in stroke demonstrating an
early and late peak? What level of monitoring is required and
how feasible is that within the confines of an acute stroke unit
and the patient-to-nurse staffing ratios available? Will more
rigorous identification of hyperglycemia in the setting of
acute stroke have implications for earlier detection underly-
ing diabetes or impaired glucose tolerance? The challenges
inherent in answering these questions are considerable, but
the potential impact on our ability to provide optimal man-
agement of stroke patients is greater still.
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None.
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